Fierce Pharma

APRIL 19, 2024

The Swiss pharma has now secured an FDA approval in the post-surgical setting as it continues to test the drug in additional patient populations. . | Roche isn’t content with Alecensa being the best-selling ALK inhibitor in metastatic lung cancer.

FDA 297

FDA Pharma Patients 297

Pharmacy Times

APRIL 19, 2024

With this approval, alectinib is the first anaplastic lymphoma kinase inhibitor to be approved for patients with ALK-positive, early-stage non-small cell lung cancer.

Patients 47

Patients FDA 47

PharmExec

APRIL 17, 2024

Alvotech’s and Teva's Selarsdi (ustekinumab-aekn), the second FDA-approved biosimilar to Stelara, is indicated to treat patients aged 6 years and above with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and for patients aged 6 years and above with active psoriatic arthritis.

FDA 52

FDA Patients 52

Pharmacy Times

APRIL 18, 2024

With the first FDA-approved option hitting shelves soon, pharmacists can advise patients on the best methods to prevent pregnancy

Patients 48

Patients FDA 48

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

A recent draft from the FDA provides valuable insight. Learning Objectives: Dose-response curves and patient treatment: How do pharmacologic and toxicologic principles apply to the dosing of drugs in clinical development? What will the future hold for clinical research?

FDA

European Pharmaceutical Review

APRIL 16, 2024

Novartis has released new data from the first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with the rare kidney disease IgA nephropathy (IgAN). Fabhalta was given a positive opinion from the CHMP of the EMA in March 2024, according to Novartis.

Food and Drug Administration 83

Food and Drug Administration Food Safety Medicine 83

European Pharmaceutical Review

APRIL 17, 2024

Roche’s twice-yearly, 10-minute subcutaneous injection of OCREVUS ® (ocrelizumab) has shown significant promise for patients with either with relapsing or primary progressive multiple sclerosis (RMS or PPMS). percent had no relapse) in patients through 48 weeks of the treatment.

Food and Drug Administration 71

Food and Drug Administration Safety Medicine Food 71